Research Repository UCD

Title	The efficacy and prescription of neuromuscular electrical stimulation (NMES) in adult cancer survivors: a systematic review and meta-analysis
Authors(s)	O'Connor, Dominic, Caulfield, Brian, Lennon, Olive
Publication date	2018-12
Publication information	O'Connor, Dominic, Brian Caulfield, and Olive Lennon. "The Efficacy and Prescription of Neuromuscular Electrical Stimulation (NMES) in Adult Cancer Survivors: A Systematic Review and Meta-Analysis" 26, no. 12 (December, 2018).
Publisher	Springer
Item record/more information	http://hdl.handle.net/10197/10889
Publisher's statement	This is a post-peer-review, pre-copyedit version of an article published in Supportive Care in Cancer. The final authenticated version is available online at: http://dx.doi.org/10.1007/s00520-018-4342-7 .
Publisher's version (DOI)	10.1007/s00520-018-4342-7

Downloaded 2023-04-07T10:52:29Z

The UCD community has made this article openly available. Please share how this access benefits you. Your story matters! (@ucd_oa)

© Some rights reserved. For more information

The efficacy and prescription of neuromuscular electrical stimulation (NMES) in adult cancer survivors: a systematic review and meta-analysis

Dominic O'Connor MSc¹, Brian Caulfield PhD¹, Olive Lennon PhD²

¹The Insight Centre for Data Analytics, O'Brien Centre for Science, University College Dublin, Ireland; ²UCD School of Public Health, Physiotherapy and Sports Science, Health Sciences Centre, University College Dublin, Ireland.

* Corresponding Author: Mr. Dominic O'Connor,
The Insight Centre for Data Analytics,
O'Brien Centre for Science
University College Dublin,
Bellfield Campus,
Dublin,
Ireland,
Email: dominic.oconnor@insight-centre.org
Phone: +353 (89) 605 1993

Dominic O'Connor: ORCID ID - 0000-0002-3054-0636

ABSTRACT:

Purpose

This study aims to; 1) summarise and critically evaluate the effects of neuromuscular electrical stimulation (NMES) on indices of health and quality of life (QoL) in adult cancer survivors, 2) assess the safety of NMES as a rehabilitation method in this population, and 3) identify commonly used NMES treatment parameters and describe treatment progression.

Methods

A systematic search of four electronic databases targeted studies evaluating the effects of NMES on physical function, aerobic fitness, muscle strength, body composition and health related quality of life (HR-QoL) in adult cancer survivors, published through March 2018. Two reviewers independently reviewed and appraised the risk of bias of each study

Results

Nine studies were included. Meta analyses found that the overall pooled effect favoured NMES for improving muscle strength, but the standardised mean difference was not significant (0.36, 95% CI -0.25, 0.96). Further meta-analyses indicated that NMES significantly improved HR-QoL (0.36, 95% CI 0.10, 0.62), with notable gains identified under the subcategories QoL Function (0.87, 95% CI 0.32, 1.42). Current NMES prescription is not-standardised and NMES is prescribed to target secondary complications of treatment. Risk of bias was high for most studies

Conclusions

NMES use in adult cancer survivors is an emerging field and current literature is limited by studies of poor quality, and a lack of adequately powered RCT's. Existing evidence suggests NMES is safe and may be more effective than usual care for improving HR-QoL. Prescription and progression should be tailored for the individual based on functional deficits.

KEYWORDS: neuromuscular electrical stimulation, adult cancer survivors, rehabilitation, oncology, physical function

Annual cancer diagnosis rates (>14 million per year) are set to increase by 50% before 2030 [1]. However, mortality from cancer is decreasing. Five-year survival rates in the US for all cancer combined have improved by almost 20%, from 49% in the 1970's to ~70% in 2016 [2]. Similar trends have been reported in Europe with mortality rates in men and women falling by 8% and 3% respectively since 2011 [3]. These favourable trends are linked to improved screening and more effective antineoplastic treatments [4].

Although cancer treatments (e.g. chemotherapy and hormone therapy) can be efficacious, they can lead to long-term side effects such as fatigue, muscle loss, and reductions in functional capacity [5]. Exercise which targets both the neuromuscular and cardiovascular systems is currently recommended to help offset some of the complications of treatment with guidelines recommending 150 mins of moderate or 75mins of vigorous aerobic exercise coupled with 2-3 resistance training (RT) sessions per week regardless of disease progression [6].

Nevertheless, exercise is not always possible due to treatment complications or contraindications to aerobic exercise and RT. Reports suggest that only ~35% of cancer survivors achieve current recommendations [7, 8] with breathlessness, fatigue, weakness and poor balance cited as common issues affecting basic exercise participation such as walking [9]. Thus, pragmatic alternatives to traditional exercise methods are required.

Neuromuscular electrical stimulation (NMES) involves controlled muscular contractions generated by electrical impulses delivered through surface electrodes, usually placed on major muscle groups such as the quadriceps and hamstrings [10]. The evoked contractions have proven efficacy in improving muscle strength and cardiorespiratory fitness across a variety of populations [11–18]. Thus, physician supervised NMES exercise to enhance the neuromuscular and cardiovascular systems has applicability within the cancer population to prevent the complications associated with treatment and improve health related quality of life (HR-QoL). However, NMES uptake clinically is low [19] and currently no published, high-level evidence supports its application in cancer survivorship.

Therefore, the objectives of this review are to evaluate published research investigating the use of NMES exercise in adult cancer survivors; synthesise the evidence evaluating its application in improving physical function and HR-QoL; assess the safety of NMES exercise in cancer populations and determine if specific prescription and progression patterns could be identified with NMES application in cancer survivorship.

METHODS

A systematic search and review of the literature was conducted using the PRISMA guidelines [20]. The following databases were searched up to March 2018: PubMed (1949 – 2018), EMBASE (1947 – 2018), CINAHL (1982 – 2018), and The Cochrane Library (1993 – 2018). A protocol detailing the planned search strategy and method for analysis for this review was registered online with PROSPERO, a register of systematic review (CRD42017073519).

Eligibility criteria

Selection criteria for inclusion in this review comprised: 1) article or abstract of original research, 2) population of adult cancer survivors, 3) interventions detailing NMES, and 4) measurement of outcomes pre-NMES and post-NMES to evaluate treatment effectiveness. No limitations were placed by study methodology to allow for a more comprehensive overview of this nascent area.

Exclusion criteria included studies involving transcutaneous electrical stimulation (TENS) for cancer pain or spinal cord stimulation.

Search

A search strategy (*Appendix 1*), guided by an institutional liaison Librarian, was based on the PICO method. The population was adult cancer survivors, the intervention was NMES, the comparator was no intervention or standard care and outcomes were physical function, aerobic fitness (cardiovascular capacity (VO_{2max}) or VO_{2peak} or submaximal exercise capacity), muscle strength, body composition, and HR-QoL.

Study selection

Figure 1 details the study selection process. Identified studies were screened by title by one reviewer (DO'C). Remaining studies were independently screened by abstract by two reviewers (DO'C., OL). Identified full text manuscripts were again independently reviewed by two reviewers (DO'C., OL). Reasons for exclusion were recorded.

Data collection process

Two reviewers (DO'C and OL) extracted data variables: type of study, study population (age, sex, disease type and disease stage), intervention, outcome measures, and results (*Table 1*). In addition, NMES intervention prescription and progression data were extracted using frequency, intensity, type and time (FITT) along with reported safety/adverse events (*Table 2*).

Quality assessment

Included studies were assessed independently by two reviewers (DO'C and OL) using the Effective Public Health Practice Project Quality Assessment Tool (EPHPP). In addition, the Cochrane Risk of Bias Tool was used for randomised controlled trials (RCTs). Disagreements were resolved by consensus.

Data synthesis

A narrative approach to analysis was first proposed, summarising all included studies by outcomes of interest. Secondary outcomes of NMES prescription and progression, and safety were also summarised narratively. Where two or more RCTs measured the same outcome, meta-analysis was proposed whereby differences between NMES based interventions and comparator groups from pre-to post intervention would be calculated using Review Manager (v5.2) software. Continuous outcome measures would be expressed as the mean difference from pre-to post treatment in each group and variances derived from standard deviations. Where studies reported median and ranges, these would be converted to mean and standard deviation using a previously published method [21]. A fixed effects inverse-variance meta-analysis for mean differences with 95% confidence intervals (CI) between NMES-based interventions and control groups was proposed. A small number of studies were anticipated in this area, making it difficult to estimate the between studies variance with any precision. Where treatment outcomes were measured using different outcome measures a standardised mean difference was calculated and where measured at more than one time point, the last measurement was used in the meta-analysis conducted. Sub-analysis for distinct follow-up periods would be conducted, where data permit.

RESULTS

Study selection

Figure 1 presents the flowchart of the study selection process. A total of 896 studies were identified from the databases. Eight full text articles and one abstract were included for final analysis; four RCTs [22–25], one case

control study [26], three interventional cohort studies [27–29], and one case report [30]. Authors were contacted for further information for four additional studies identified [31–34]. Following three contact attempts with the corresponding authors, studies were excluded where no response was received.

Risk of bias within studies

The overall risk of bias was deemed high in 3 RCTs [22–24], with 1 study marked as unclear [25]. When all studies were evaluated using the EPHPP tool, 2 of the 9 studies received a strong global rating for quality [23, 29], 5 a moderate quality rating [22, 24, 25, 28, 30] and 1 was rated as weak [26]. With limited data available to the reviewers, the abstract included in the review [27] was also rated as weak.

Participant demographics

A total of 229 adult cancer survivors from the 9 studies were included in this review. Of these, 111 were males (48.5%) and 118 were women (51.5%). Two studies included only women [23, 30]. The pooled mean age of participants (n=229) in this review was 57.9 ± 9.3 years (min/max: 47/68 years). Participant body mass index (BMI-kg/m²) was reported in 5 studies (n = 120) and ranged from 23.1 to 30.47 kg/m².

Cancer types: breast cancer [23], non-small cell lung cancer (NSCLC) [22, 24], metastatic lung cancer [30], cerebral glioma [27], nasopharyngeal carcinoma [26], low rectal cancer [29], and foregut cancers including liver, pancreas and stomach [25]. One study comprised a heterogeneous group including lung (n=5), gastrointestinal (n=1), breast (n=1), ovarian (n=1), endometrial (n=1) and haematological cancers (n=1) [28]

Intervention

Location: Three interventions were home based [22, 24, 28]. Other locations included hospital outpatient departments [23, 26, 29, 30], and in-patient hospital rehabilitation units [25, 27]. Five studies used an experimental control group. Two studies reported using a “no NMES” treatment control group [22, 24], two reported usual care controls [23, 26]. One study reported the contralateral limb as the control [25]. Three studies reported no control group [27–29].

Evidence supporting NMES application in Cancer survivorship

Meta-analyses

Sufficient data were extracted from RCTs to enable meta-analysis of two outcomes of interest, muscle strength as measured by fixed [22] and manual muscle test dynamometry [24], and HR-QoL as measured by the EORTC QLQ C-30 [24] and the FACT-B+4 [23]. In each measure, the higher the score the better the outcome.

Strength: Data were pooled from two RCT studies with a total of 44 participants with lung cancer (Figure 2) [22, 24]. Compared to usual care controls, the standardised mean effect of the NMES intervention on muscle strength was not statistically significant (SMD 0.36, 95% CI -0.25, 0.96, $Z=1.15$, $p=0.25$).

Health related Quality of life: Data were pooled from two RCT studies with a total of 60 participants with breast cancer or lung cancer (Figure 3) [23, 24]. Compared to usual care controls, meta-analysis demonstrates that the standardised mean effect of an NMES intervention for HR-QoL was significantly greater (SMD 0.36, 95% CI 0.10, 0.62, $Z=2.69$, $p=0.007$). When considered under sub-categories of HR-QoL, the gains identified were notable in the QoL Functional domain (SMD 0.87, 95% CI 0.32, 1.42, $Z=3.09$, $p=0.002$).

Narrative summary of individual studies

Effects of NMES on body function and structure

Submaximal exercise capacity

Exercise capacity was measured using the 6-minute walk test (6MWT) in 2 studies [28, 30] and the endurance shuttle walk test (ESWT) [22] in another. Maddocks et al., [22] in a RCT involving NSCLC patient, recording 0 or 1 on the Eastern Cooperative Oncology Group performance status and at least 4 weeks post treatment, reported no significant difference between the NMES and “no NMES” groups in the ESWT (-20m vs -158m, $p=0.27$). Windholz et al., [28] in their prospective pilot study reported no significant change in 6MWT performance after the intervention period from baseline (-21.1m, $p=0.7$). Crevenna et al., [30] in a case study reported improvements of 44% in 6MWT performance (420m to 603m).

Functional strength

One study analysed functional strength using the timed up and go test (TUG) [30]. One study used the sit to stand test (STS) [28]. Windholz et al., [28] reported no significant change in STS time from pre-to post NMES intervention (-1.2s, $p=0.3$). Crevenna et al [30] in their case report reported a 20% reduction in TUG performance with this equating to a 1s reduction in time taken to complete the test (pre-6s vs post-5s).

Body composition

Dual Energy X-ray absorptiometry (DXA) was used to assess thigh and whole body lean tissue mass in one study [24]. No significant difference between the NMES and control groups was noted in thigh lean mass ($p=0.44$) or whole body lean mass ($p=0.31$).

Biomarkers of muscle hypertrophy and atrophy

One study assessed biomarkers of muscle hypertrophy and muscle atrophy [25]; After 4 days of 30mins/day NMES application, no significant effect of NMES treatment on IGF-1Ea mRNA was noted in the treated limb in comparison to the contralateral control limb ($p=0.516$). Of note, total RNA content was 26% greater in the NMES treated leg than in the contralateral control limb ($9.6\mu\text{g}/\text{mg}$ vs $7.6\mu\text{g}/\text{mg}$; $p=0.033$). In addition, sarcoplasmic protein content increased by 20%, and this change was significant when compared to the control limb ($p=0.029$). NMES treatment had no effect on myofibrillar proteins ($p=0.393$). In the NMES limb, the expression of ubiquitin-conjugated proteins of sarcoplasmic fraction were significantly less (-23%) than that of the control limb ($p=0.0005$). Proteasome activity was significantly reduced in the NMES limb also (-34%) in comparison to the control ($p=0.048$).

Effects of NMES on HR-QoL

Six studies measured HR-QoL using diverse outcome measures, often reflecting the cancer type or aim of treatment. One study [24] used the multidimensional European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Crevenna et al., [30] assessed quality of life using the SF-36 Health survey. Lin et al., [26] assessed the swallowing aspect of HR-QoL using the M.D. Anderson Dysphagia Inventory (MDADI). Belmonte et al., [23] measured HR-QoL using the Functional Assessment of Cancer Therapy Questionnaire for Breast Cancer Therapy version 4 (FACT-B+4). Rozumenko & Khoroshun [27] measured HR-QoL using a Karnofsky Performance Status (KPS) scale of functional impairment. Kuo et al [29] measured faecal incontinence HR-QOL using the Wexner Cleveland Clinic Florida Grading scale.

Maddocks et al., [24] reported no significant changes following NMES in the EORTC QLQ-C30's 6 sub-scales (General Health score, Physical, Role, Emotional, Cognitive, Social) when compared to "no NMES" controls.

Belmonte et al., [23] reported significant within group pre-vs post HR-QoL mean change scores in the NMES group across FACT-B+4 summary scores: FACT-General ($p=0.006$), FACT-Breast ($p=0.013$) and FACT-Trial Outcome Index (TOI) ($p=0.015$). However, when mean change scores were compared, no significant difference was reported across the three HR-QoL summary-scales (FACT-General, $p=0.197$; FACT-Breast, $p=0.130$; FACT-TOI, $p=0.074$). Lin et al., [26] in their case control study reported that FES significantly improved swallowing HR-QoL from 45.1 to 53.1 ($p=0.003$). Kuo et al., [29] in their interventional cohort study reported significant improvements in the Wexner's score post NMES treatment (17.74 vs 12.93; $p<0.001$). Rozumenko & Khoroshun [27] reported the proportion of patients with a KPS>70 score before treatment and post rehabilitation as the outcome of interest, noting an increase from 43.7% to 83.5%, no p value was reported. The case report by Crevenna et al., [30] showed improvements in all HR-QoL scales of the SF-36 with the exception of the social functioning sub-scale.

Safety of NMES

Three studies reported no adverse events [22, 24, 30] in lung cancer populations when NMES was applied to the lower limbs. One study employing NMES for lymphedema treatment following breast cancer reported dermatological adverse events [23]., including erysipelas on the upper limb ($n=1$), skin irritation ($n=1$) and erythema on the back of the hand ($n=1$). Four studies did not report adverse events as an outcome [25, 26, 28, 29]. In one study, available in abstract form, NMES safety was indeterminate, despite attempts to contact the authors [27].

Stimulation parameters: Three studies employed a biphasic symmetrical current [22, 24, 30]. Kuo et al [29] reported a square waveform. Rozumenko & Khoroshun [27] reported an asymmetrical waveform. Four studies did not report waveform [23, 25, 26, 28]. Pulse frequency was reported in all studies (range: 0.31Hz - 63.3Hz). Pulse duration was reported in 8 studies (range: 250 μ s – 700 μ s). Duty cycles varied from 2s – 12s in the on phase and 4s – 30s in the off phase. Three studies commented on the rationale for protocol selection [22, 24, 30]; justifying for pragmatic reasons, protocols previously used successfully in chronic obstructive pulmonary disease (COPD) and in heart failure patients.

Electrode placement: Two studies reported stimulation of the anterior thigh over the quadriceps [22, 24, 25]. One study reported the motor point of the vastus medialis oblique distally, and over the midpoint of the

quadriciceps muscle belly more proximally [28]. Crevenna et al., [30] reported quadriciceps and gluteal stimulation. Belmonte et al., [23] stimulated areas corresponding to lymphnodal stations. Kuo et al., [29] stimulated the anal canal and Lin et al., [26] placed electrodes between the hyoid bone and thyroid cartilage. One study reported that electrodes were placed in areas according to the clinical indications of motional defects, although no further information was provided by the authors upon request [27].

Session duration: NMES session duration varied from 5 mins [27] to 60 mins [26].

Duration of treatment: Four studies reported treatment durations as the number of sessions delivered (4 sessions: [25]; 12 sessions: [29]; 15 sessions: [26]; 7-12 sessions: [27]). The duration of NMES treatment reported in remaining studies in weeks varied from 2 weeks [23] to 11 weeks [24].

FITT Prescription and progression patterns (Table 2): Only 4 studies reported progression patterns [22, 24, 27, 28]. One study reported progression from 30 min/day to 60 min/day after week 1 [22]. One reported progression from 5 to 15 mins [27]. Two studies reported a progression in the proportion of the treatment which was active stimulation. This progressed weekly from 2s on: 10s off (11%) to 5s on: 25s off (18%) to 10s on: 30s off (25%) and constant there after [22, 24].

Discussion

The overall findings of this study suggest that NMES may be more effective than standard care for improving HR-QoL (Figure 2.). The current evidence does not support the use of NMES over and above usual care for improving submaximal exercise capacity, functional capacity or body composition. Meta-analysis of strength drawn from a total of 44 participants (Figure 3.), showed the overall pooled effect favouring application of NMES for improving muscle strength but results were non-significant. No major adverse events following NMES application in cancer survivors were reported in the studies reviewed. This paper provides a comprehensive overview of the current evidence base in NMES research and oncology, not limited by year, language or study type. However, high risk of bias noted in 3 of the 4 RCTs limits the current conclusions relating to higher level evidence that can be drawn. This is clearly an emerging field with a lack of large, adequately powered RCTs.

Cancer survivors experience poorer HR-QoL in response to disease/treatment [35]. Therefore, this review evaluated the efficacy of NMES for improving domains of HR-QoL. Overall meta-analysis demonstrated effectiveness of NMES over standard care for improving HR-QoL, and in particular function QoL. Conflicting findings were reported in overall studies and mediating factors such as fatigue and exercise intensity must be considered in the interpretation of the findings. Maddocks et al., [24] reported no significant differences between NMES and “no NMES” control across 6 HR-QoL subscales in patients receiving chemotherapy. However, ongoing treatments are linked to increased fatigue levels [36]. Moderate to vigorous intensity voluntary exercise delivered during active treatment has been shown to improve HR-QoL and function QoL [35]. Crevenna et al., [30] reported both improvement in aerobic exercise capacity and better HR-QoL following NMES in a case study, with the exception of the “social functioning” subscale. Therefore, moderate to vigorous intensity NMES prescription which can improve aerobic exercise capacity and dissipate fatigue may be required to see sufficient improvements in HR-QoL subscales such as function QoL.

Specific HR-QoL outcomes were reported in studies for faecal incontinence in low rectal cancer [29] and dysphagia in nasopharyngeal carcinoma patients [26], highlighting the diverse nature of HR-QoL assessment in cancer survivors. In breast cancer patients with lymphedema, Belmonte et al., [23] reported improvements in HR- QoL following NMES which met the minimal clinically important change score as reported by Eton et al., [37], a finding not replicated in the control group receiving manual drainage. While the magnitude of change was larger in the NMES group statistical power was noted as a limitation limiting conclusions that can be drawn.

Interestingly, muscle strength was not a commonly reported outcome and overall, meta-analysis of pooled effect from 2 RCTs did not demonstrate effectiveness of NMES over standard care in this outcome. However, two factors must be considered. First, Maddocks et al [22] reported similar improvements in lower limb muscle strength (+22%) to those reported in a healthy elderly population (+15%) after 8 weeks of HF-NMES [13]. A small sample size conferring a lack of statistical power may have contributed to this finding. Secondly, poor adherence to un-supervised home-based interventions may lead to an inadequate exercise dosage for a training effect. Exercise intensity, mostly reported as visible muscle contractions or maximum tolerable intensities may also be a contributing factor. Strength improvements from NMES are linearly related to NMES training intensity and therapeutic exercise intensities of 15-25% of maximal voluntary contraction (MVC) have been

noted [38]. No studies included in this review reported training intensity as a percentage of MVC. In addition, a habituation period of 1-2 may be required to achieve these strengthening thresholds and to identify non-responders [19]. Indeed, 10% of patient groups and elderly cohorts do not tolerate NMES [19, 39] and an extended intervention period may be required to realise the true magnitude of adaptation to NMES stimulus in the elderly [40]. Therefore, habituation to NMES should be considered in future studies. This will allow practitioners to identify non-responders, and for them consider alternative therapeutic strategies.

The optimal parameters for the safe use of NMES across all cancer populations cannot be determined from the studies included in this review. Only 3 studies [22, 24, 30] explicitly reported no adverse events and these were all related to individuals with lung cancer (NSCLC and metastatic lung cancer). NMES, in the main appeared to be well tolerated with only one study reporting minor adverse events [23]. Skin irritations are not uncommon in NMES application [41], however it is interesting to note the population (post breast cancer lymphedema patients) and the treatment parameters employed in this case (Carrier frequency -0.31-6.16Hz, modulation between 400-1200Hz, low offset voltage between +12 and -12 V). The author did report that after stimulation intensity was reduced, skin irritations did not reoccur. The high intensity in this study was likely required due to the higher levels of fluid present within the tissue.

Prescription and progression patterns relating to NMES treatment provided to adult cancer survivors appears to be underdeveloped and a lack of standardisation was evident across studies. Despite a call for standardisation over 30 years ago [42], this remains a common find in NMES research [43]. The diverse cancer populations in the included studies is acknowledged and may in part contribute to this finding with respect to the site of application, and variables such as frequency and intensity, and electrode size and placement. NMES was predominantly prescribed in those unable to partake in voluntary exercise due to their underlying disease or who were determined to be at risk of harm [30] and to combat secondary complications of cancer treatment relating to muscle weakness with 7 studies involving participants who were post treatment. Studies included in this review where indices of physical function were the primary outcomes [22, 24, 30, 44] adopted a homogenous prescription approach (3-5x/week, 50-63.3Hz, 300-400us). Although this prescription has been successful and safe in other patient groups (i.e. COPD, CHF), including those with implantable cardioverter defibrillators (when delivered to lower limbs) [45, 46], such a general approach in cancer survivors may mask NMES's potential, given that cancer survivors can experience day to day variability in their readiness to train. The

prescription of voluntary exercise in cancer survivorship is mostly individualised and adapted to optimise the therapeutic effect and minimise injury [47]. However, whilst voluntary exercise prescription adheres to the principles of training, NMES prescription in cancer survivors currently does not.

Specificity, the prescription of exercise designed to improve the primary outcome of interest, is another recognised principle of exercise training in cancer survivorship [47] that warrants further consideration in NMES prescription to improve physical function. Three of the included studies which considered the effects of NMES on submaximal exercise capacity employed high frequency protocols (50-63.3Hz), and demonstrated negative results. The application of high frequency NMES favours adaptations in muscle strength [12]. Current exercise oncology guidelines recommend the inclusion of aerobic exercise [6] and where the outcomes of interest include both strength and exercise capacity, employing both low and high frequency NMES modalities may be more efficacious in future studies with acknowledgement that adaptations to low and high frequency NMES are uniquely different [48].

In this review, NMES sessions were mostly delivered in the hospital or rehabilitation and outpatient clinics with only 3 being home-based interventions. Supervised sessions allow for regular oversight and are pragmatic as dose and compliance can be easily monitored. However, patient preferences may lean towards home-based interventions [9]. Self-report diaries are commonly used to monitor adherence to unsupervised home-based interventions; however, over-reporting is common [49]. Therefore, it is possible home-based NMES may suffer from these same limitations, potentially masking benefits to primary outcomes. Future studies should consider cancer type and use adequate methods to monitor adherence for home-based interventions such as regular home visits or technologies such as app based systems which can be used to monitor adherence, collect data and provide remote support [50].

Conclusion

The use of NMES in cancer rehabilitation is an emerging field. The current literature is limited by studies of poor quality and a lack of adequately powered RCTs. Existing studies suggest that NMES is safe and may be more effective than usual care for improving HR-QoL. However, its effects on objective measures of strength, body composition and functional measures is less clear. A periodised approach including greater progression and defined prescriptive guidelines to maximise adherence to NMES prescription in the future may help

improve its efficacy. High quality RCTs in cancer survivorship to definitively evaluate the effectiveness of NMES are required where the parameters chosen and progression patterns are tailored to the individual and outcomes of interest.

Funding: D O'Connor is supported by a grant from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement no. 722012

Conflict of Interest: The authors declare that they have no conflict of interest.

References

1. Askoxylakis V, Thieke C, Pleger ST, et al (2010) Long-term survival of cancer patients compared to heart failure and stroke: A systematic review. *BMC Cancer* 10:105 . doi: 10.1186/1471-2407-10-105
2. Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. *CA Cancer J Clin* 67:7–30 . doi: 10.3322/caac.21387
3. Malvezzi M, Carioli G, Bertuccio P, et al (2017) European cancer mortality predictions for the year 2017, with focus on lung cancer. *Ann Oncol* 28:1117–1123 . doi: 10.1093/annonc/mdx033
4. Cormie P, Zopf EM, Zhang X, Schmitz KH (2017) The impact of exercise on cancer mortality, recurrence, and treatment-related adverse effects. *Epidemiol Rev* 39:71–92 . doi: 10.1093/epirev/mxx007
5. Courneya KS, Friedenreich CM (2001) Framework PEACE: an organizational model for examining physical exercise across the cancer experience. *Ann Behav Med* 23:263–272 . doi: 10.1207/S15324796ABM2304_5
6. Schmitz KH, Courneya KS, Matthews C, et al (2010) American college of sports medicine roundtable on exercise guidelines for cancer survivors. *Med. Sci. Sports Exerc.* 42:1409–1426
7. Mason C, Alfano CM, Smith AW, et al (2013) Long-term physical activity trends in breast cancer survivors. *Cancer Epidemiol Biomarkers Prev* 22:1153–1161 . doi: 10.1158/1055-9965.EPI-13-0141.Long-term
8. Sturgeon KM, Fisher C, McShea G, et al (2017) Patient preference and timing for exercise in breast cancer care. *Support. Care Cancer* 1–8
9. Maddocks M, Armstrong S, Wilcock A (2011) Exercise as a supportive therapy in incurable cancer:

419 Exploring patient preferences. *Psychooncology* 20:173–178 . doi: 10.1002/pon.1720

420 10. Hultman E, Sjöholm H, Jäderholm-Ek I, Krynicky J (1983) Evaluation of methods for electrical
421 stimulation of human skeletal muscle in situ. *Pflügers Arch Eur J Physiol* 398:139–141 . doi:
422 10.1007/BF00581062

423 11. Maffiuletti NA (2006) The use of electrostimulation exercise in competitive sport. *Int J Sports Physiol*
424 *Perform* 1:406–407

425 12. Bax L, Staes F, Verhagen A (2005) Does neuromuscular electrical stimulation strengthen the quadriceps
426 femoris? A systematic review of randomised controlled trials. *Sports Med* 35:191–212 . doi:
427 10.2165/00007256-200535030-00002

428 13. Caulfield B, Prendergast A, Rainsford G, Minogue C (2013) Self directed home based electrical muscle
429 stimulation training improves exercise tolerance and strength in healthy elderly. *Conf Proc . Annu Int*
430 *Conf IEEE Eng Med Biol Soc IEEE Eng Med Biol Soc Annu Conf* 2013:7036–7039 . doi:
431 10.1109/EMBC.2013.6611178

432 14. Banerjee P, Caulfield B, Crowe L, Clark AL (2009) Prolonged Electrical Muscle Stimulation Exercise
433 Improves Strength, Peak VO₂, and Exercise Capacity in Patients With Stable Chronic Heart Failure. *J*
434 *Card Fail* 15:319–326 . doi: 10.1016/j.cardfail.2008.11.005

435 15. Roig M, Reid WD (2009) Electrical stimulation and peripheral muscle function in COPD: A systematic
436 review. *Respir. Med.* 103:485–495

437 16. Brüggemann AK, Mello CL, Dal Pont T, et al (2017) Effects of Neuromuscular Electrical Stimulation
438 During Hemodialysis on Peripheral Muscle Strength and Exercise Capacity: A Randomized Clinical
439 Trial. *Arch Phys Med Rehabil* 98:822–831.e1 . doi: 10.1016/j.apmr.2016.12.009

440 17. Crognale D, Vito G De, Grosset J-F, et al (2013) Neuromuscular Electrical Stimulation Can Elicit
441 Aerobic Exercise Response Without Undue Discomfort in Healthy Physically Active Adults. *J Strength*
442 *Cond Res* 27:208–215 . doi: 10.1519/JSC.0b013e318252f5e5

443 18. Carty A, McCormack K, Coughlan GF, et al (2012) Increased aerobic fitness after neuromuscular
444 electrical stimulation training in adults with spinal cord injury. *Arch Phys Med Rehabil* 93:790–795 .
445 doi: 10.1016/j.apmr.2011.10.030

446 19. Maffiuletti NA, Gondin J, Place N, et al (2017) The Clinical Use of Neuromuscular Electrical
447 Stimulation for Neuromuscular Rehabilitation: What Are We Overlooking? *Arch Phys Med Rehabil.*
448 doi: 10.1016/j.apmr.2017.10.028

- 449 20. Moher D, Shamseer L, Clarke M, et al (2015) Preferred reporting items for systematic review and meta-
450 analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 4:1 . doi: 10.1186/2046-4053-4-1
- 451 21. Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the
452 sample size, median, range and/or interquartile range. *BMC Med Res Methodol* 14:135 . doi:
453 10.1186/1471-2288-14-135
- 454 22. Maddocks M, Lewis M, Chauhan A, et al (2009) Randomized Controlled Pilot Study of Neuromuscular
455 Electrical Stimulation of the Quadriceps in Patients with Non-Small Cell Lung Cancer. *J Pain Symptom*
456 *Manage* 38:950–956 . doi: 10.1016/j.jpainsymman.2009.05.011
- 457 23. Belmonte R, Tejero M, Ferrer M, et al (2012) Efficacy of low-frequency low-intensity electrotherapy in
458 the treatment of breast cancer-related lymphoedema: a cross-over randomized trial. *Clin Rehabil*
459 26:607–618 . doi: 10.1177/0269215511427414
- 460 24. Maddocks M, Halliday V, Chauhan A, et al (2013) Neuromuscular electrical stimulation of the
461 quadriceps in patients with non-small cell lung cancer receiving palliative chemotherapy: a randomized
462 phase II study. *PLoS One* 8:e86059 . doi: 10.1371/journal.pone.0086059
- 463 25. Strasser EM, Stattner S, Karner J, et al (2009) Neuromuscular electrical stimulation reduces skeletal
464 muscle protein degradation and stimulates insulin-like growth factors in an age- and current-dependent
465 manner: A randomized, controlled clinical trial in major abdominal surgical patients. *Ann Surg*
466 249:738–743 . doi: 10.1097/SLA.0b013e3181a38e71
- 467 26. Lin P-H, Hsiao T-Y, Chang Y-C, et al (2011) Effects of functional electrical stimulation on dysphagia
468 caused by radiation therapy in patients with nasopharyngeal carcinoma. *Support Care Cancer* 19:91–99 .
469 doi: 10.1007/s00520-009-0792-2
- 470 27. Rozumenko VD, Khoroshun AP (2012) Electrostimulation and laser therapy in postoperative recovery
471 of cerebral glioma patients. *Photodiagnosis Photodyn Ther* 9:S31
- 472 28. Windholz T, Swanson T, Vanderbyl BL, et al (2014) Correction: The feasibility and acceptability of
473 neuromuscular electrical stimulation to improve exercise performance in patients with advanced cancer:
474 a pilot study. *BMC Palliat Care* 13:33–35 . doi: 10.1186/1472-684X-13-33
- 475 29. Kuo L-JJ, Lin Y-KY-CKYC, Lai C-HH, et al (2015) Improvement of Fecal Incontinence and Quality of
476 Life by Electrical Stimulation and Biofeedback for Patients with Low Rectal Cancer after
477 Intersphincteric Resection. *Arch Phys Med Rehabil* 96:1442–1447 . doi: 10.1016/j.apmr.2015.03.013
- 478 30. Crevenna R, Marosi C, Schmidinger M, et al (2006) Neuromuscular electrical stimulation for a patient

479 with metastatic lung cancer - A case report. *Support Care* 14:970–973 . doi: 10.1007/s00520-006-0033-
480 x

481 31. Gerovasili V, Stefanidis K, Vitzilaios K, et al (2009) Electrical muscle stimulation preserves the muscle
482 mass of critically ill patients: a randomized study. *Crit Care* 13:R161 . doi: 10.1186/cc8123

483 32. Gruther W, Kainberger F, Fialka-Moser V, et al (2010) Effects of neuromuscular electrical stimulation
484 on muscle layer thickness of knee extensor muscles in intensive care unit patients: a pilot study. *J*
485 *Rehabil Med* 42:593–597 . doi: 10.2340/16501977-0564

486 33. Kaddu-Mulindwa D, Klostermann A, Bewarder M, et al (2017) Safety, feasibility and effectiveness of
487 electrical muscle stimulation in hospitalized patients undergoing autologous or allogeneic stem cell
488 transplantation and intensive chemotherapy. *Haematologica* 102:600 . doi:
489 10.3324/haematol.2016.147132

490 34. Olivier C, Delourme J, Cortot A, et al (2014) A feasibility study of pulmonary rehabilitation at home in
491 patients with lung cancer or malignant pleural mesothelioma treated by (radio-)chemotherapy. *Eur*
492 *Respir J* 44:

493 35. Mishra SI, Scherer RW, Snyder C, et al (2012) Exercise interventions on health-related quality of life
494 for people with cancer during active treatment. *Cochrane database Syst Rev* 8:CD008465 . doi:
495 10.1002/14651858.CD008465.pub2

496 36. Bower JE (2014) Cancer-related fatigue--mechanisms, risk factors, and treatments. *Nat. Rev. Clin.*
497 *Oncol.* 11:597–609

498 37. Eton DT, Cella D, Yost KJ, et al (2004) A combination of distribution- and anchor-based approaches
499 determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. *J Clin*
500 *Epidemiol* 57:898–910 . doi: 10.1016/j.jclinepi.2004.01.012

501 38. Maddocks M, Nolan CM, Man WDC, et al (2016) Neuromuscular electrical stimulation to improve
502 exercise capacity in patients with severe COPD: A randomised double-blind, placebo-controlled trial.
503 *Lancet Respir Med* 4:27–36 . doi: 10.1016/S2213-2600(15)00503-2

504 39. Vivodtzev I, Rivard B, Gagnon P, et al (2014) Tolerance and physiological correlates of neuromuscular
505 electrical stimulation in COPD: A pilot study. *PLoS One* 9: . doi: 10.1371/journal.pone.0094850

506 40. Churchward-Venne TA, Tieland M, Verdijk LB, et al (2015) There are no nonresponders to resistance-
507 type exercise training in older men and women. *J Am Med Dir Assoc* 16:400–411 . doi:
508 10.1016/j.jamda.2015.01.071

41. Sheffler LR, Chae J (2007) Neuromuscular electrical stimulation in neurorehabilitation. *Muscle Nerve* 35:562–590 . doi: 10.1002/mus.20758
42. Singer KP, DE Domenico G, Strauss G (1987) Electro-motor stimulation research methodology and reporting: a need for standardization. *Aust J Physiother* 33:43–48 . doi: 10.1016/S0004-9514(14)60583-3
43. Maffiuletti NA, Minetto MA, Farina D, Bottinelli R (2011) Electrical stimulation for neuromuscular testing and training: State-of-the art and unresolved issues. *Eur J Appl Physiol* 111:2391–2397 . doi: 10.1007/s00421-011-2133-7
44. Windholz T, Swanson T, Vanderbyl BL, Jagoe RT (2014) Correction: The feasibility and acceptability of neuromuscular electrical stimulation to improve exercise performance in patients with advanced cancer: a pilot study. *BMC Palliat Care* 13:33–35 . doi: 10.1186/1472-684X-13-33
45. Crevenna R, Mayr W, Keilani M, et al (2003) Safety of a combined strength and endurance training using neuromuscular electrical stimulation of thigh muscles in patients with heart failure and bipolar sensing cardiac pacemakers. *Wien Klin Wochenschr*. doi: 10.1007/BF03040887
46. Cenik F, Schoberwalter D, Keilani M, et al (2016) Neuromuscular electrical stimulation of the thighs in cardiac patients with implantable cardioverter defibrillators. *Wien. Klin. Wochenschr*.
47. Sasso JP, Eves ND, Christensen JF, et al (2015) A framework for prescription in exercise-oncology research. *J Cachexia Sarcopenia Muscle* 115–124 . doi: 10.1002/jcsm.12042
48. Atherton PJ, Babraj J, Smith K, et al (2005) Selective activation of AMPK-PGC-1 α or PKB-TSC2-mTOR signaling can explain specific adaptive responses to endurance or resistance training-like electrical muscle stimulation. *FASEB J Off Publ Fed Am Soc Exp Biol* 19:786–788 . doi: 10.1096/fj.04-2179fje
49. Prince S, Adamo K, Hamel M, et al (2008) A comparison of direct versus self-report measures for assessing physical activity in adults: a systematic review. *Int J Behav Nutr Phys Act* 5:56 . doi: 10.1186/1479-5868-5-56
50. Chughtai M, Piuze N, Yakubek G, et al (2017) Use of an App-Controlled Neuromuscular Electrical Stimulation System for Improved Self-Management of Knee Conditions and Reduced Costs. *Surg Technol Int* 31:

540

541
542
543 Identification
544
545
546
547
548 Screening
549
550
551
552
553 Eligibility
554
555
556
557
558
559 Included
560
561

562

563

564

565

566

567 **Figure 1.** PRISMA flow diagram of the study selection process

568

569

570

571

572

573

574

Figure 2. Pooled analysis of strength for NMES versus usual care.

Figure 3. Pooled analysis of NMES versus usual care in HR-QoL domains